Nxstage Medical Inc (NXTM) 24.78 $NXTM Research
Post# of 273254
Posted On: 09/26/2016 1:03:41 AM
Nxstage Medical Inc (NXTM) 24.78 $NXTM
Research Reports Coverage on Select Healthcare Stocks -- ZELTIQ Aesthetics, Globus Medical, Align Technology, and Nxstage Medical
PR Newswire - Thu Sep 22, 6:45AM CDT
On Wednesday, September 21, 2016, the NASDAQ Composite ended the trading session at 5,295.18, up 1.03%; the Dow Jones Industrial Average edged 0.90% higher, to finish at 18,293.70; and the S&P 500 closed at 2,163.12, up 1.09%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com initiated research reports on the following Healthacre equities: ZELTIQ Aesthetics Inc. (NASDAQ: ZLTQ), Globus Medical Inc. (NYSE: GMED), Align Technology Inc. (NASDAQ: ALGN), and Nxstage Medical Inc. (NASDAQ: NXTM). Learn more about these stocks by downloading their comprehensive and free reports at:
NXTM: 24.78 (-0.17), ZLTQ: 40.24 (+0.31), ALGN: 94.13 (-1.54), GMED: 22.58 (-0.22)
NxStage Launches First of Many NxGen Features and Capabilities
PR Newswire - Mon Aug 08, 7:00AM CDT
LAWRENCE, Mass., Aug. 8, 2016 NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of dialysis products, today announced the release of new enhanced priming features, the first of many upcoming capabilities of its next generation hemodialysis system. The features are designed to be used for home treatments with current and next generations of the NxStage System One.
NXTM: 24.78 (-0.17)
NxStage Reports Second Quarter Financial Results And Raises Full-Year Revenue Guidance
PR Newswire - Thu Aug 04, 7:06AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today reported second quarter revenue above the top end of its guidance.
NXTM: 24.78 (-0.17)
Medical Product Stock Earnings on Aug 4: NXTM, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:56AM CDT
Here, we take a look at four Medical product stocks set to report their quarterly figures on Aug 4.
NXTM: 24.78 (-0.17), AGIO: 53.03 (unch), ATRC: 16.14 (-0.36), HRC: 60.78 (-0.06)
NxStage to Present at Canaccord Genuity 36th Annual Growth Conference
PR Newswire - Tue Aug 02, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced that Jeffrey H. Burbank, Chief Executive Officer, and Matthew Towse, Chief Financial Officer, will present at the Canaccord Genuity 36th Annual Growth Conference on Wednesday, August 10th at 8:30 a.m. ET in Boston, MA.
NXTM: 24.78 (-0.17)
Technical Roundup on Medical Appliances and Equipment Stocks -- ZELTIQ Aesthetics, Align Technology, Nxstage Medical, and Nevro
PR Newswire - Mon Aug 01, 7:15AM CDT
One of the U.S. Healthcare sector's biggest segments, the Medical Appliances and Equipment is expected to face challenges due to stiff competition and economic uncertainties. However, constant need and demand for medical instruments should continue to drive industry growth, and the segment is anticipated to grow at a CAGR rate of about 6% through 2017, according to Espicom's 2014 report. Stock-Callers.com looks closely at the following stocks today: ZELTIQ Aesthetics Inc. (NASDAQ: ZLTQ), Align Technology Inc. (NASDAQ: ALGN), Nxstage Medical Inc. (NASDAQ: NXTM), and Nevro Corp. (NYSE: NVRO). Sign up today and download for free the research reports for the stocks covered today at:
NXTM: 24.78 (-0.17), ZLTQ: 40.24 (+0.31), ALGN: 94.13 (-1.54), NVRO: 102.00 (+1.24)
Why Investors Love These Medical Appliances & Equipment's Stocks? - Align Technology, ZELTIQ Aesthetics, Amedica, and Nxstage Medical
PR Newswire - Wed Jun 22, 6:45AM CDT
Growth is expected for the U.S. Medical Appliances and Equipment industry as demand for healthcare continues to rise. In today's pre-market research, Stock-Callers.com shifts its attention on these four equities for investors' close review: Align Technology Inc. (NASDAQ: ALGN), ZELTIQ Aesthetics Inc. (NASDAQ: ZLTQ), Amedica Corp. (NASDAQ: AMDA), and Nxstage Medical Inc. (NASDAQ: NXTM). Learn more about these stocks and receive your complimentary trade alerts at:
NXTM: 24.78 (-0.17), ZLTQ: 40.24 (+0.31), ALGN: 94.13 (-1.54), AMDA: 0.96 (unch)
Uptrend Call Working As NxStage Medical Stock Rises 33.4% (NXTM)
Comtex SmarTrend(R) - Fri Jun 10, 1:01PM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on March 7th, 2016 at $15.61. In approximately 3 months, NxStage Medical has returned 33.38% as of today's recent price of $20.82.
NXTM: 24.78 (-0.17)
Nxstage Medical (NXTM) Catches Eye: Stock Jumps 5.6%
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 7:40AM CDT
Nxstage Medical, Inc. (NXTM) saw its shares almost 6% in the last trading session.
NXTM: 24.78 (-0.17), BAX: 47.49 (-0.71)
Uptrend Call Working As NxStage Medical Stock Rises 25.8% (NXTM)
Comtex SmarTrend(R) - Fri Jun 03, 1:20AM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on March 7th, 2016 at $15.61. In approximately 3 months, NxStage Medical has returned 25.82% as of today's recent price of $19.64.
NXTM: 24.78 (-0.17)
NxStage Medical Has Returned 19.2% Since SmarTrend Recommendation (NXTM)
Comtex SmarTrend(R) - Thu May 26, 1:52PM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on March 7th, 2016 at $15.61. In approximately 3 months, NxStage Medical has returned 19.15% as of today's recent price of $18.60.
NXTM: 24.78 (-0.17)
NxStage Announces Second Quarter 2016 Investor Conference Schedule
PR Newswire - Tue May 24, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced that Jeffrey H. Burbank, Chief Executive Officer, plans to participate in the following schedule of investor conferences. Where applicable, a webcast of the event will be made available at http://ir.nxstage.com/.
NXTM: 24.78 (-0.17)
NxStage Medical Cuts Its Losses as Critical Care Leads Sales Higher
Dan Caplinger, The Motley Fool - Motley Fool - Wed May 04, 10:44AM CDT
Image source: NxStage Medical. Profitability often eludes small companies seeking to expand their businesses, and for home dialysis specialist NxStage Medical , the challenge of spending money on research and development while also marketing its...
NXTM: 24.78 (-0.17)
NxStage Reports First Quarter Financial Results
PR Newswire - Wed May 04, 7:05AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today reported first quarter financial results above the top end of its guidance.
NXTM: 24.78 (-0.17)
NxStage to Present at the Deutsche Bank 41st Annual Health Care Conference
PR Newswire - Mon Apr 25, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced that Jeffrey H. Burbank, Chief Executive Officer, plans to present at the Deutsche Bank 41st Annual Health Care Conference on Thursday, May 5, 2016 at 8:40 a.m. ET in Boston, MA. A webcast of the event will be made available at http://ir.nxstage.com/.
NXTM: 24.78 (-0.17)
NxStage® to Report First Quarter 2016 Financial Results
PR Newswire - Mon Apr 11, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced plans to release its financial results for the first quarter ended March 31, 2016, on Wednesday, May 4, 2016, before the opening of the financial markets.
NXTM: 24.78 (-0.17)
Why NxStage Medical, Inc. Guided Lower Today
Brian Orelli, The Motley Fool - Motley Fool - Wed Feb 10, 3:48PM CST
What: NxStage Medical is down 14% near the closing bell after releasing disappointing guidance during its fourth-quarter earnings release this morning. So what: Fourth-quarter revenue was pretty strong, up 12% year over year. NxStage Medical...
NXTM: 24.78 (-0.17)
NxStage Reports Record Fourth Quarter and Full-Year 2015 Revenue
PR Newswire - Wed Feb 10, 7:02AM CST
Highlights:
NXTM: 24.78 (-0.17)
NxStage® to Report Fourth Quarter and Full Year 2015 Financial Results
PR Newswire - Tue Jan 19, 7:00AM CST
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2015, on Wednesday, February 10, 2016, before the opening of the financial markets.
NXTM: 24.78 (-0.17)
NxStage System One Use Continues in Haiti Six Years After Earthquake
PR Newswire - Wed Jan 13, 10:00AM CST
To coincide with the sixth anniversary of the 2010 Haiti earthquake, NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of dialysis products, is recognizing the efforts of medical leaders and support teams in helping to save the lives of people suffering from acute kidney injury (AKI) after the devastating earthquake in Haiti. Immediately following the disaster, Brian Remillard, M.D., Section Chief of Nephrology and Hypertension at Dartmouth-Hitchcock Medical Center (DHMC) led a coordinated effort to bring the portable NxStage® System One(TM) to Haiti to provide on-site dialysis therapy to injured survivors. With support from NxStage, Remillard's efforts have included emergency response following the earthquake, as well as long-term initiatives focused on improvements in renal care for patients in Haiti.
NXTM: 24.78 (-0.17)
Research Reports Coverage on Select Healthcare Stocks -- ZELTIQ Aesthetics, Globus Medical, Align Technology, and Nxstage Medical
PR Newswire - Thu Sep 22, 6:45AM CDT
On Wednesday, September 21, 2016, the NASDAQ Composite ended the trading session at 5,295.18, up 1.03%; the Dow Jones Industrial Average edged 0.90% higher, to finish at 18,293.70; and the S&P 500 closed at 2,163.12, up 1.09%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com initiated research reports on the following Healthacre equities: ZELTIQ Aesthetics Inc. (NASDAQ: ZLTQ), Globus Medical Inc. (NYSE: GMED), Align Technology Inc. (NASDAQ: ALGN), and Nxstage Medical Inc. (NASDAQ: NXTM). Learn more about these stocks by downloading their comprehensive and free reports at:
NXTM: 24.78 (-0.17), ZLTQ: 40.24 (+0.31), ALGN: 94.13 (-1.54), GMED: 22.58 (-0.22)
NxStage Launches First of Many NxGen Features and Capabilities
PR Newswire - Mon Aug 08, 7:00AM CDT
LAWRENCE, Mass., Aug. 8, 2016 NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of dialysis products, today announced the release of new enhanced priming features, the first of many upcoming capabilities of its next generation hemodialysis system. The features are designed to be used for home treatments with current and next generations of the NxStage System One.
NXTM: 24.78 (-0.17)
NxStage Reports Second Quarter Financial Results And Raises Full-Year Revenue Guidance
PR Newswire - Thu Aug 04, 7:06AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today reported second quarter revenue above the top end of its guidance.
NXTM: 24.78 (-0.17)
Medical Product Stock Earnings on Aug 4: NXTM, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:56AM CDT
Here, we take a look at four Medical product stocks set to report their quarterly figures on Aug 4.
NXTM: 24.78 (-0.17), AGIO: 53.03 (unch), ATRC: 16.14 (-0.36), HRC: 60.78 (-0.06)
NxStage to Present at Canaccord Genuity 36th Annual Growth Conference
PR Newswire - Tue Aug 02, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced that Jeffrey H. Burbank, Chief Executive Officer, and Matthew Towse, Chief Financial Officer, will present at the Canaccord Genuity 36th Annual Growth Conference on Wednesday, August 10th at 8:30 a.m. ET in Boston, MA.
NXTM: 24.78 (-0.17)
Technical Roundup on Medical Appliances and Equipment Stocks -- ZELTIQ Aesthetics, Align Technology, Nxstage Medical, and Nevro
PR Newswire - Mon Aug 01, 7:15AM CDT
One of the U.S. Healthcare sector's biggest segments, the Medical Appliances and Equipment is expected to face challenges due to stiff competition and economic uncertainties. However, constant need and demand for medical instruments should continue to drive industry growth, and the segment is anticipated to grow at a CAGR rate of about 6% through 2017, according to Espicom's 2014 report. Stock-Callers.com looks closely at the following stocks today: ZELTIQ Aesthetics Inc. (NASDAQ: ZLTQ), Align Technology Inc. (NASDAQ: ALGN), Nxstage Medical Inc. (NASDAQ: NXTM), and Nevro Corp. (NYSE: NVRO). Sign up today and download for free the research reports for the stocks covered today at:
NXTM: 24.78 (-0.17), ZLTQ: 40.24 (+0.31), ALGN: 94.13 (-1.54), NVRO: 102.00 (+1.24)
Why Investors Love These Medical Appliances & Equipment's Stocks? - Align Technology, ZELTIQ Aesthetics, Amedica, and Nxstage Medical
PR Newswire - Wed Jun 22, 6:45AM CDT
Growth is expected for the U.S. Medical Appliances and Equipment industry as demand for healthcare continues to rise. In today's pre-market research, Stock-Callers.com shifts its attention on these four equities for investors' close review: Align Technology Inc. (NASDAQ: ALGN), ZELTIQ Aesthetics Inc. (NASDAQ: ZLTQ), Amedica Corp. (NASDAQ: AMDA), and Nxstage Medical Inc. (NASDAQ: NXTM). Learn more about these stocks and receive your complimentary trade alerts at:
NXTM: 24.78 (-0.17), ZLTQ: 40.24 (+0.31), ALGN: 94.13 (-1.54), AMDA: 0.96 (unch)
Uptrend Call Working As NxStage Medical Stock Rises 33.4% (NXTM)
Comtex SmarTrend(R) - Fri Jun 10, 1:01PM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on March 7th, 2016 at $15.61. In approximately 3 months, NxStage Medical has returned 33.38% as of today's recent price of $20.82.
NXTM: 24.78 (-0.17)
Nxstage Medical (NXTM) Catches Eye: Stock Jumps 5.6%
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 7:40AM CDT
Nxstage Medical, Inc. (NXTM) saw its shares almost 6% in the last trading session.
NXTM: 24.78 (-0.17), BAX: 47.49 (-0.71)
Uptrend Call Working As NxStage Medical Stock Rises 25.8% (NXTM)
Comtex SmarTrend(R) - Fri Jun 03, 1:20AM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on March 7th, 2016 at $15.61. In approximately 3 months, NxStage Medical has returned 25.82% as of today's recent price of $19.64.
NXTM: 24.78 (-0.17)
NxStage Medical Has Returned 19.2% Since SmarTrend Recommendation (NXTM)
Comtex SmarTrend(R) - Thu May 26, 1:52PM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on March 7th, 2016 at $15.61. In approximately 3 months, NxStage Medical has returned 19.15% as of today's recent price of $18.60.
NXTM: 24.78 (-0.17)
NxStage Announces Second Quarter 2016 Investor Conference Schedule
PR Newswire - Tue May 24, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced that Jeffrey H. Burbank, Chief Executive Officer, plans to participate in the following schedule of investor conferences. Where applicable, a webcast of the event will be made available at http://ir.nxstage.com/.
NXTM: 24.78 (-0.17)
NxStage Medical Cuts Its Losses as Critical Care Leads Sales Higher
Dan Caplinger, The Motley Fool - Motley Fool - Wed May 04, 10:44AM CDT
Image source: NxStage Medical. Profitability often eludes small companies seeking to expand their businesses, and for home dialysis specialist NxStage Medical , the challenge of spending money on research and development while also marketing its...
NXTM: 24.78 (-0.17)
NxStage Reports First Quarter Financial Results
PR Newswire - Wed May 04, 7:05AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today reported first quarter financial results above the top end of its guidance.
NXTM: 24.78 (-0.17)
NxStage to Present at the Deutsche Bank 41st Annual Health Care Conference
PR Newswire - Mon Apr 25, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced that Jeffrey H. Burbank, Chief Executive Officer, plans to present at the Deutsche Bank 41st Annual Health Care Conference on Thursday, May 5, 2016 at 8:40 a.m. ET in Boston, MA. A webcast of the event will be made available at http://ir.nxstage.com/.
NXTM: 24.78 (-0.17)
NxStage® to Report First Quarter 2016 Financial Results
PR Newswire - Mon Apr 11, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced plans to release its financial results for the first quarter ended March 31, 2016, on Wednesday, May 4, 2016, before the opening of the financial markets.
NXTM: 24.78 (-0.17)
Why NxStage Medical, Inc. Guided Lower Today
Brian Orelli, The Motley Fool - Motley Fool - Wed Feb 10, 3:48PM CST
What: NxStage Medical is down 14% near the closing bell after releasing disappointing guidance during its fourth-quarter earnings release this morning. So what: Fourth-quarter revenue was pretty strong, up 12% year over year. NxStage Medical...
NXTM: 24.78 (-0.17)
NxStage Reports Record Fourth Quarter and Full-Year 2015 Revenue
PR Newswire - Wed Feb 10, 7:02AM CST
Highlights:
NXTM: 24.78 (-0.17)
NxStage® to Report Fourth Quarter and Full Year 2015 Financial Results
PR Newswire - Tue Jan 19, 7:00AM CST
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2015, on Wednesday, February 10, 2016, before the opening of the financial markets.
NXTM: 24.78 (-0.17)
NxStage System One Use Continues in Haiti Six Years After Earthquake
PR Newswire - Wed Jan 13, 10:00AM CST
To coincide with the sixth anniversary of the 2010 Haiti earthquake, NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of dialysis products, is recognizing the efforts of medical leaders and support teams in helping to save the lives of people suffering from acute kidney injury (AKI) after the devastating earthquake in Haiti. Immediately following the disaster, Brian Remillard, M.D., Section Chief of Nephrology and Hypertension at Dartmouth-Hitchcock Medical Center (DHMC) led a coordinated effort to bring the portable NxStage® System One(TM) to Haiti to provide on-site dialysis therapy to injured survivors. With support from NxStage, Remillard's efforts have included emergency response following the earthquake, as well as long-term initiatives focused on improvements in renal care for patients in Haiti.
NXTM: 24.78 (-0.17)
(0)
(0)Scroll down for more posts ▼